Karsten, Nora
Kolben, Thomas
Mahner, Sven
Beyer, Susanne
Meister, Sarah
Kuhn, Christina
Schmoeckel, Elisa
Wuerstlein, Rachel
Harbeck, Nadia
Ditsch, Nina
Jeschke, Udo http://orcid.org/0000-0003-2623-3235
Friese, Klaus
Kolben, Theresa Maria
Funding for this research was provided by:
Heuer-Stiftung
Ludwig-Maximilians-Universität München
Article History
Received: 13 April 2021
Accepted: 17 August 2021
First Online: 12 September 2021
Declarations
:
: Thomas Kolben holds stock of Roche AG, relative employed at Roche AG. Theresa M. Kolben is employed at Roche AG, holds stock of Roche AG. Rachel Wuerstlein has received research and travel support as well as honoraria by Roche, Celegne, AstraZeneca, MSD, Lilly, and Pfizer Oncology. Sven Mahner has been supported by AstraZeneca, Bayer, Boehringer Ingelheim, Jenapharm, GSK, JanssenCilag, Medac, MSD, Pharmamar, Roche, Tesaro, and Teva. All other authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.